|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1617181920212223242526...6768» |
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 26, 2015
P2, N=100, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2016 --> Mar 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) - Nov 26, 2015
P1/2, N=60, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2015 Trial primary completion date: Aug 2011 --> Nov 2016
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Nov 26, 2015
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Aug 2011 --> Nov 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial suspension: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 25, 2015
P1/2, N=69, Suspended, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Suspended
- melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
P1 data: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) - Nov 24, 2015
P1, N=26, Recruiting, Sponsor: Spectrum Health Hospitals
Recruiting --> Suspended Trial primary completion date: Dec 2015 --> Jul 2016
- || aspirin / Generic mfg., hydroxyurea / Generic mfg.
New P3 trial: FAST: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (clinicaltrials.gov) - Nov 24, 2015
P3, N=2250, Not yet recruiting, Sponsor: Assistance Publique - H
- Enrollment change, Trial initiation date, Trial primary completion date, Head-to-Head: Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Nov 22, 2015
P3, N=8, Terminated, Sponsor: Octapharma
Trial primary completion date: Dec 2015 --> Jul 2016 N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008
- Avastin (bevacizumab) / Roche
Trial termination, Trial primary completion date: ALEGORI: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - Nov 21, 2015
P2/3, N=80, Terminated, Sponsor: Hospices Civils de Lyon
N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008 Recruiting --> Terminated | Trial primary completion date: May 2016 --> Jun 2015; DSMB's decision following the first step analysis
- dinaciclib (MK-7965) / Merck (MSD)
Trial primary completion date, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Nov 19, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated | Trial primary completion date: May 2016 --> Jun 2015; DSMB's decision following the first step analysis Trial primary completion date: Jun 2016 --> Jun 2017
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New trial: LEGEND: A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (clinicaltrials.gov) - Nov 18, 2015
P=N/A, N=220, Not yet recruiting, Sponsor: Genesis Pharma S.A.
- roneparstat (LB401) / Leadiant Biosci
Trial primary completion date, Metastases: SST0001 (Roneparstat) in Advanced Multiple Myeloma (clinicaltrials.gov) - Nov 17, 2015
P1, N=30, Recruiting, Sponsor: Sigma Tau Research Switzerland SA
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Oct 2015 --> Jun 2016
- |||| Alphanate (human plasma derived von Willebrand factor/FVIII complex) / Grifols, Advate (octocog alfa) / Takeda
Trial completion, Trial primary completion date: SIPPET: Survey of Inhibitors in Plasma-Product Exposed Toddlers (clinicaltrials.gov) - Nov 17, 2015
P4, N=303, Completed, Sponsor: Fondazione Angelo Bianchi Bonomi
Trial primary completion date: Oct 2015 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Nov 2014 --> May 2015
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2015
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> May 2015 Trial primary completion date: Oct 2015 --> Mar 2016
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2015
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- Darzalex (daratumumab) / J&J
Trial completion: A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 17, 2015
P1, N=9, Completed, Sponsor: Janssen Pharmaceutical K.K.
Trial primary completion date: Oct 2015 --> Jun 2016 Active, not recruiting --> Completed
- New P1 trial: "Novo C Plus" Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects (clinicaltrials.gov) - Nov 17, 2015
P1, N=32, Completed, Sponsor: Semmelweis University
- dexamethasone injection / Generic mfg.
Enrollment open, Monotherapy: A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma (clinicaltrials.gov) - Nov 17, 2015
P2, N=30, Recruiting, Sponsor: Boston Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Xofigo (radium Ra-223 dichloride) / Bayer
New P1/2 trial, Combination therapy: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma (clinicaltrials.gov) - Nov 16, 2015
P1/2, N=226, Not yet recruiting, Sponsor: Bayer
- lenalidomide / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change: Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 15, 2015
P1/2, N=3, Active, not recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting N=45 --> 3
- Enrollment closed: Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=250, Active, not recruiting, Sponsor: New York University School of Medicine
N=45 --> 3 Recruiting --> Active, not recruiting
- Trial completion: Geriatric Assessments in Senior Adults With Multiple Myeloma (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=42, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment closed: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Nov 15, 2015
P1, N=10, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment closed, Enrollment change: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Nov 15, 2015
P2, N=5, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting | N=14 --> 5
- Trial completion, Trial primary completion date: ACTMM: C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=30, Completed, Sponsor: Chang Gung Memorial Hospital
Suspended --> Active, not recruiting | N=14 --> 5 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> May 2015
- Biomarker, Phase classification: Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial (clinicaltrials.gov) - Nov 14, 2015
P2, N=24, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> May 2015 Phase classification: P=N/A --> P2
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer (clinicaltrials.gov) - Nov 12, 2015
P1/2, N=31, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Phase classification: P=N/A --> P2 Trial primary completion date: May 2012 --> Aug 2012
- Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Nov 11, 2015
P2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2012 --> Aug 2012 Trial primary completion date: Jun 2016 --> Oct 2015
- befovacimab (BAY 1093884) / Bayer
Enrollment open: A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (clinicaltrials.gov) - Nov 11, 2015
P1, N=26, Recruiting, Sponsor: Bayer
Trial primary completion date: Jun 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- New trial: FF8: The Fear F8ctor Study - Does Fear Induce a Blood Curdling State? (clinicaltrials.gov) - Nov 11, 2015
P=N/A, N=24, Completed, Sponsor: Leiden University Medical Center
- Trial completion, Trial primary completion date: UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 10, 2015
P2, N=233, Completed, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2015
- Trial completion, Enrollment change, Trial primary completion date: Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 10, 2015
P1/2, N=25, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2015 Active, not recruiting --> Completed | N=15 --> 25 | Trial primary completion date: Jul 2013 --> Jun 2014
- |||| P2 data: IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (clinicaltrials.gov) - Nov 10, 2015
P2, N=84, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed | N=15 --> 25 | Trial primary completion date: Jul 2013 --> Jun 2014 Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Apr 2014
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Nov 10, 2015
P2, N=208, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Apr 2014 Recruiting --> Active, not recruiting | N=160 --> 208
- || zotiraciclib (TG02) / Cothera Biosci
Metastases: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (clinicaltrials.gov) - Nov 9, 2015
P1, N=120, Recruiting, Sponsor: Tragara Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=160 --> 208 Trial primary completion date: Mar 2016 --> Jun 2016
- decitabine / Generic mfg.
Enrollment change, Trial initiation date: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Nov 9, 2015
P2, N=60, Recruiting, Sponsor: Shandong University
Trial primary completion date: Mar 2016 --> Jun 2016 N=20 --> 60 | Initiation date: Jun 2014 --> Jun 2015
- | staphylococcal protein A (PRTX-100) / Protalex
Enrollment open: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=30, Recruiting, Sponsor: Protalex, Inc.
N=20 --> 60 | Initiation date: Jun 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- oprozomib (ONX 0912) / Amgen
Trial completion, Enrollment change, Trial primary completion date: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 5, 2015
P1/2, N=9, Completed, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=74 --> 9 | Trial primary completion date: Oct 2015 --> Jan 2015
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Nov 5, 2015
P1, N=18, Recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed | N=74 --> 9 | Trial primary completion date: Oct 2015 --> Jan 2015 Trial primary completion date: Dec 2015 --> May 2016
- | New P2 trial: iTACTIC: Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (clinicaltrials.gov) - Nov 2, 2015
P2, N=392, Not yet recruiting, Sponsor: Queen Mary University of London
- ||| Enrollment open: Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (clinicaltrials.gov) - Nov 2, 2015
P=N/A, N=300, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2015 --> May 2016 Not yet recruiting --> Enrolling by invitation
- | Trial completion: Colorado Adult Joint Assessment Scale (CAJAS) Validation (clinicaltrials.gov) - Oct 30, 2015
P=N/A, N=29, Completed, Sponsor: Bayer
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment closed: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Oct 29, 2015
P2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- || carfilzomib / Generic mfg.
Clinical: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (clinicaltrials.gov) - Oct 28, 2015
P2, N=100, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- | Zydelig (idelalisib) / Gilead
Enrollment open, Trial initiation date: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstr (clinicaltrials.gov) - Oct 28, 2015
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment open, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 28, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015 Suspended --> Recruiting
- | Biostate (factor VIII/von Willebrand factor) / CSL Behring
Enrollment open: Study of Voncento® in Subjects With Von Willebrand Disease (clinicaltrials.gov) - Oct 28, 2015
P4, N=30, Recruiting, Sponsor: CSL Behring
Suspended --> Recruiting Not yet recruiting --> Recruiting
- ||||||| NovoThirteen (catridecacog) / Novo Nordisk
Trial completion: mento 2: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (clinicaltrials.gov) - Oct 28, 2015
P3, N=63, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Biomarker, Trial primary completion date: Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Oct 24, 2015
P1, N=18, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Dec 2012
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
P1 data: CHAMPION 2: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (clinicaltrials.gov) - Oct 24, 2015
P1, N=27, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Jun 2014 --> Dec 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Sep 2015
- carfilzomib / Generic mfg.
Clinical: Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease (clinicaltrials.gov) - Oct 23, 2015
P1, N=32, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2015